MiNK Therapeutics, Inc. Rings the Opening Bell in Celebration of its IPO
ABOUT THIS EVENT
MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, visits the Nasdaq MarketSite in Times Square.
In honor of the occasion, Jennifer Buell, Ph.D., Chief Executive Officer, rings the Opening Bell.